{"id":"ql2108-injection","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL2108760","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Unfortunately, there is limited information available on QL2108 injection's mechanism of action.","oneSentence":"QL2108 injection's mechanism is not publicly available.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:30:51.067Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT06884891","phase":"PHASE3","title":"A Phase Ⅲ Comparative Study of QL2108 to Dupixent®","status":"NOT_YET_RECRUITING","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2025-04","conditions":"Atopic Dermatitis","enrollment":520},{"nctId":"NCT06614907","phase":"PHASE1","title":"A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2024-08-31","conditions":"Atopic Dermatitis","enrollment":198}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":595852,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"QL2108 injection","genericName":"QL2108 injection","companyName":"Qilu Pharmaceutical Co., Ltd.","companyId":"qilu-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}